International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors

Overview of attention for article published in Diabetes Care, February 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 16 news outlets
policy: 1 policy source
twitter: 180 X users
facebook: 2 Facebook pages
wikipedia: 2 Wikipedia pages

reddit: 1 Redditor
guideline: 2 clinical guideline sources
bluesky: 2 Bluesky users
podcasts: 1 podcast

Readers on

mendeley: 322 Mendeley

So far, Altmetric has seen 17 news stories from 16 outlets.

SGLT Inhibitors Protect the Heart and Kidneys: Why Is Type 1 Diabetes Still the Exception?

Diabetes In Control, 17 Sep 2026

SGLT inhibitors have changed the treatment landscape for cardiovascular and kidney disease, particularly in people with type 2…

Therapie des Typ-1-Diabetes im Umbruch: Dauermessung und Immunmodulation

Medscape, 31 Oct 2019

Auf dem EASD-Kongress in Barcelona präsentierten Forscher spannende Therapien für den Typ-1-Diabetes.

Europe embraces, FDA rejects use of SGLT inhibitors for type 1 diabetes

Healio.com, 23 Jul 2019

In the spring, the European Commission approved two non-insulin oral agents for use as adjuncts to insulin for adults with type…

ADA Issues Time-in-Range Targets for CGM Use

Medical Health News, 14 Jun 2019

The consensus report was presented at the 79th Scientific Sessions of the American Diabetes Association in San Francisco…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 13 additional news stories.